Efficacy and safety of anti-CGRP monoclonal antibodies for chronic migraine prophylaxis in patients treated with botulinum toxin A: A prospective monocentric study
Since the high burden of chronic migraine (CM), it is challenging to identify the best prevention treatment. Based on the preclinical evidence about the different therapeutic targets of onabotulinumtoxinA (BT-A), acting on C-fibers, and anti-CGRP monoclonal antibodies (mAbs), acting on Aδ-fibers, th...
Saved in:
Main Authors: | Calogera Butera (Author), Ilaria Cetta (Author), Roberta Messina (Author), Laura Zanandrea (Author), Roberto Santangelo (Author), Bruno Colombo (Author), Massimo Filippi (Author), Ubaldo Del Carro (Author) |
---|---|
Format: | Book |
Published: |
SAGE Publishing,
2024-10-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Monoclonal antibodies blocking CGRP for prevention of migraine
by: Alicja Maziarczyk, et al.
Published: (2023) -
Change of CGRP Plasma Concentrations in Migraine after Discontinuation of CGRP-(Receptor) Monoclonal Antibodies
by: Bianca Raffaelli, et al.
Published: (2023) -
Anti-CGRP monoclonal antibodies in the treatment of migraine in women: impact on menstrual relared migraine and algodysmenorrhea
by: Anna V. Berdnikova, et al.
Published: (2023) -
The impact of topiramate, botulinum toxin type A, and CGRP-antibodies on medication overuse headache in patients with chronic migraine: A protocol for systematic review and meta-analysis
by: Samita Giri, et al.
Published: (2022) -
New Trends in Migraine Pharmacology: Targeting Calcitonin Gene-Related Peptide (CGRP) With Monoclonal Antibodies
by: Damiana Scuteri, et al.
Published: (2019)